GCG and obesity disorder: Tirzepatide, a novel dual glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist, has gained recognition as an effective option for managing both T2DM and obesity by targeting multiple metabolic pathways (5–8).